Skip to content
DataLookout
Menu

ZELANCT06897839

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 50 → 56 locations
    • Study description expanded, about 40 words
  2. Notable Eligibility criteria expanded, about 11 words
    • Study sites: 50 to 49
  3. Minor Site details revised at 11 of 50 sitesv10
  4. Minor Site details revised at 3 of 50 sitesv9
  5. Minor Site details revised at 4 of 50 sitesv8
  6. Minor Trial sites expanded: 20 → 50 locationsv7
  7. Minor Study sites: 18 to 20v6
  8. Notable Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Dec 31, 2027 to Mar 31, 2028
    • Study completion date: Feb 28, 2030 to Apr 30, 2030
    • Site details revised at 18 of 18 sites
    v5
  9. Notable Phase: Phase 3 to Phase 2/3v3 Show 8 more changesShow less
    • Eligibility criteria revised
    • Enrollment target: 316 to 366
    • Study sites: 15 to 18
    • Primary completion date: Aug 30, 2027 to Dec 31, 2027
    • Study completion date: Jul 30, 2029 to Feb 28, 2030
    • Secondary endpoints: 15 to 23
    • Study arms: 2 to 3
    • Study title expanded, about 2 words
  10. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 15 of 15 sites
    v2
  11. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death
Timeframe: Week 36 Post Menstrual Age (PMA)

Secondary (19)

Ventilator-free days
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD)
Incidence of death
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death assessed on 3 consecutive days at week 36 PMA
The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD
Show 14 moreShow less
The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD assessed on 3 consecutive days at week 36 PMA
Total average days on supplemental oxygen
Total average days on continuous positive airway pressure (CPAP) or high flow nasal cannula (HFNC)
Extubation rate
Average preductal oxygen saturation measured by oxygen saturation to fraction of inspired oxygen ratio (SF)
Average preductal oxygen saturation measured by oxygen saturation index (OSI)
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death after excluding subjects with death at ≤ 14 days postnatal age
Survival at 6, 12 and 24 months corrected age
Average number of hospitalizations and days in hospital
Incidence of chronic respiratory morbidity
Incidence of neurodevelopmental disability among survivors
Severity and frequency of treatment-emergent adverse events (TEAEs) or treatment-emergent serious adverse events (TESAEs)
Immunogenicity analysis

Arms and interventions

Zelpultide alfa 4 mg/kg plus standard of careExperimental

In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 4 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.

Placebo (air-sham) plus standard of careSham comparator

In addition to the preterm neonate standard of care, approximately 1 mL of air drawn into a dosing syringe will be administered up to 7 times to neonate subjects randomized to the control (placebo) arm, following the same means and intervals as in the treatment arm.

Zelpultide alfa 6 mg/kg plus standard of careExperimental

In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 6 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.

Other: Air-sham

Drugs: Zelpultide alfa

Sites

56 sites in 10 countries

Spain 13, France 8, Germany 6, Italy 6, Poland 6, Belgium 5, Israel 5, Argentina 4, Czechia 2, Portugal 1